Cancer Vaccine Shows Early Promise Across Tumor Types
A personalized cancer vaccine proved possible to manufacture and was well tolerated in an early phase I clinical trial, researchers said.
The vaccine, known as PGV-001, was given to 13 patients with solid tumors or multiple myeloma who had a high risk of recurrence after surgery or stem cell transplant.
At last follow-up, four patients were still alive without evidence of disease and had not received subsequent therapy, four were alive and receiving therapy, three had died, and two could not be contacted for follow-up.
Comments are closed.